Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05551104 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension

Study acronym: SCARPH
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv8
  2. Start date changed from estimate of Dec 2024 to May 8, 2023v7
  3. Start date: Apr 2024 to Dec 2024
    • Primary and study completion dates: Dec 30, 2027 to Dec 2027
    v6
  4. Phase: Not applicable to Phase 3
    • Start date: Dec 2023 to Apr 2024
    v5
  5. Start date: Jun 2023 to Dec 2023v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Feb 2023 to Jun 2023
    • Study sites: 0 to 1
    v3
  2. Start date: Nov 1, 2022 to Feb 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.
Trial Details
NCT Number NCT05551104
Lead Sponsor Loma Linda University
Conditions
(from sponsor)		 Postpartum Complication, Maternal Hypertension, High Blood Pressure
Related terms Hypertension, Hypertension, Pregnancy-Induced
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov